ClinicalTrials.gg
CompletedNCT05264129TANDEMUpdated Oct 8, 2024Results posted

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

A Phase 4 interventional study of Atogepant and Ubrogepant in Episodic Migraine, sponsored by AbbVie. Completed at 37 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
263
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
15th of 21
263 · median 468
Started
2022
with 1 other
Phase 4
4 of 21
3 open now
Registered
12th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 12th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess the safety and efficacy of the combination use of ubrogepant for the acute treatment of migraine headache in participants taking atogepant once daily for preventive treatment of migraine.

Ubrogepant is an approved drug for the acute treatment of migraine. Atogepant is an approved drug for the preventive treatment of migraine. Approximately 235 adult participants with EM will be enrolled in approximately 45 sites in the United States.

Participants will receive oral atogepant tablets once daily (QD) for 12 weeks followed by continued atogepant treatment with ubrogepant tablets taken as needed for the next 12 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Episodic Migraine

Browse trials for

Keywords

  • Episodic Migraine
  • Ubrogepant
  • Atogepant
  • QULIPTA
  • UBRELVY
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD)-3, 2018.
  • History of 4 to 14 migraine days per month on average in the 3 months prior to Screening (Visit 1) in the investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  • hematologic, endocrine, cardiovascular, cerebrovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Atogepant + Ubrogepant

    Participants will receive atogepant for 12 weeks followed by atogepant + ubrogepant for 12 weeks.

    Drug: Atogepant · Drug: Ubrogepant

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. A treatment-emergent adverse event (TEAE) is an AE that occurs or worsens after receiving investigational study drug.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)

  2. Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator

    Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.

    Time frame: Up to approximately 28 weeks

  3. Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

    12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to approximately 24 weeks

  4. Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

    PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

    Time frame: Up to approximately 28 weeks

  5. Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

    C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

    Time frame: Week 1 to Week 12 for Safety Population 1; Week 12 to Week 24 for Safety Population 2

  6. Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the 4-Week Safety Follow-Up Period

    C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

    Time frame: From last dose of study drug to 4 weeks after last dose of study drug. Overall median time on atogepant treatment was 85 days.

07

Results

Posted Oct 8, 2024

Participant flow

Period 1 Atogepant (Day1 to Wk12)
Participant flow — Period 1 Atogepant (Day1 to Wk12)
MilestoneAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Started2620
Completed2210
Not completed410
Period 2 Atogepant+Ubrogepant (Wk12-24)
Participant flow — Period 2 Atogepant+Ubrogepant (Wk12-24)
MilestoneAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Started0218
Completed0203
Not completed015

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. A treatment-emergent adverse event (TEAE) is an AE that occurs or worsens after receiving investigational study drug.

Time frame:
From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Number of Participants With Adverse Events (AEs)13094
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator

Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.

Time frame:
Up to approximately 28 weeks
Reported as:
Number · participants
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator
participantsAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Erythrocytes, Hematology (10^12/L): < 0.9 * LLN33
Hematocrit (fraction of 1): < 0.9 * LLN52
Hemoglobin (g/L): < 0.9 * LLN63
Leukocytes, Hematology (10^9/L): < 0.9 * LLN37
Lymphocytes (10^9/L): < 0.7 * LLN10
Lymphocytes (10^9/L): > 1.3 * ULN01
Neutrophils (10^9/L): < 0.7 * LLN41
Neutrophils (10^9/L): > 1.3 * ULN41
Platelets (10^9/L): < 0.5 * LLN01
Alanine Aminotransferase (U/L): ≥ 3.0 * ULN30
Aspartate Aminotransferase (U/L): ≥ 3.0 * ULN10
Bicarbonate (mmol/L): < 0.9 * LLN52
Bilirubin, Chemistry (µmol/L): ≥ 1.5 * ULN22
Calcium (mmol/L): < 0.9 * LLN10
Creatine Kinase (U/L): > 2.0 * ULN95
Glucose, Chemistry (mmol/L): < 0.8 * LLN22
Glucose, Chemistry (mmol/L): > 2.0 * ULN21
Lactate Dehydrogenase (U/L): > 3.0 * ULN10
Phosphate (mmol/L): < 0.9 * LLN11
Phosphate (mmol/L): > 1.1 * ULN30
Potassium (mmol/L): < 0.9 * LLN01
Potassium (mmol/L): > 1.1 * ULN54
Protein, Chemistry (g/L): < 0.9 * LLN32
Glucose, Urinalysis: At least 1+40
Protein, Urinalysis: At least 1+3839
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to approximately 24 weeks
Reported as:
Number · participants
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
participantsAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
PR Interval (msec): ≥ 25000
QRS Interval (msec): ≥ 15001
QTcB (msec): > 50000
QTcB (msec): Increase of > 6000
QTcF (msec): > 50000
QTcF (msec): Increase of > 6000
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.

Time frame:
Up to approximately 28 weeks
Reported as:
Number · participants
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
participantsAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Sitting Systolic Blood Pressure (mmHg): ≤ 90 and Decrease of ≥ 2042
Standing Systolic Blood Pressure (mmHg): ≥ 180 and Increase of ≥ 2010
Standing Systolic Blood Pressure (mmHg): ≤ 90 and Decrease of ≥ 2022
Sitting Diastolic Blood Pressure (mmHg): ≥ 105 and Increase of ≥ 1511
Standing Diastolic Blood Pressure (mmHg): ≥ 105 and Increase of ≥ 1553
Standing Diastolic Blood Pressure (mmHg): ≤ 50 and Decrease of ≥ 1511
Sitting Pulse Rate (bpm): ≥ 120 and Increase of ≥ 1501
Sitting Pulse Rate (bpm): ≤ 50 and Decrease of ≥ 1542
Standing Pulse Rate (bpm): ≥ 120 and Increase of ≥ 1512
Standing Pulse Rate (bpm): ≤ 50 and Decrease of ≥ 1510
Weight (kg): Increase of ≥ 7%57
Weight (kg): Decrease of ≥ 7%1628
Orthostatic Systolic Blood Pressure (mmHg): ≤ -20127
Orthostatic Diastolic Blood Pressure (mmHg): ≤ -15610
Orthostatic Pulse Rate (bpm): ≥ 25107
PrimaryNumber of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

Time frame:
Week 1 to Week 12 for Safety Population 1; Week 12 to Week 24 for Safety Population 2
Reported as:
Number · participants
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
participantsAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
Suicidal Ideation02
Suicidal Behavior01
PrimaryNumber of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the 4-Week Safety Follow-Up Period

C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.

Time frame:
From last dose of study drug to 4 weeks after last dose of study drug. Overall median time on atogepant treatment was 85 days.
Reported as:
Number · participants
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the 4-Week Safety Follow-Up Period
participantsAtogepant 60 mg (Period 1)
Suicidal Ideation During Follow-Up Period1
Suicidal Behavior During Follow-Up Period0

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the end of the study. The median time on follow-up was 75.5 days from Visit 1 (Week -1) through end of Period 1 and 206 days from baseline through end of Period 2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atogepant 60 mg (Period 1)0/263 (0%)1/263 (0.4%)66/263 (25.1%)
Atogepant 60 mg + Ubrogepant 100 mg (Period 2)0/218 (0%)1/218 (0.5%)15/218 (6.9%)
Most frequent serious events
Most frequent serious events
EventAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
MYELOPATHYNervous system disorders0/2631/218
URETEROLITHIASISRenal and urinary disorders1/2630/218
Most frequent other events
Most frequent other events
EventAtogepant 60 mg (Period 1)Atogepant 60 mg + Ubrogepant 100 mg (Period 2)
COVID-19Infections and infestations23/2637/218
FATIGUEGeneral disorders17/2633/218
NAUSEAGastrointestinal disorders16/2632/218
DECREASED APPETITEMetabolism and nutrition disorders15/2632/218
CONSTIPATIONGastrointestinal disorders14/2632/218

Baseline characteristics

Overall safety population included all participants who received at least 1 dose of study drug. 263 participants were enrolled, but one participant withdrew consent prematurely discontinuing from the study before receiving study drug.

Age, Customized
Age, Customized(Participants)All Subjects
Age Group — < 20 years0
Age Group — 20 to 29 years43
Age Group — 30 to 39 years60
Age Group — 40 to 49 years71
Age Group — 50 to 59 years53
Age Group — 60 to 69 years33
Age Group — ≥ 70 years2
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female214
Male48
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Subjects
Hispanic or Latino27
Not Hispanic or Latino235
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Subjects
American Indian or Alaska Native1
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American44
White205
More than one race4
Unknown or Not Reported0
08

Study locations

37 sites
  • Achieve Clinical Research, LLC /ID# 244912
    Birmingham, Alabama 35216, United States
  • Xenoscience, Inc /ID# 243506
    Phoenix, Arizona 85004, United States
  • Excell Research, Inc /ID# 242590
    Oceanside, California 92056, United States
  • Neurological Research Institute /ID# 244161
    Santa Monica, California 90404, United States
  • George J. Rederich M.D. Inc. /ID# 242589
    Torrance, California 90505, United States
  • Diablo Clinical Research /ID# 242592
    Walnut Creek, California 94598, United States
  • Westside Center for Clinical Research /ID# 243287
    Jacksonville, Florida 32205-4785, United States
  • Suncoast Clinical Research /ID# 242463
    New Port Richey, Florida 34652, United States
  • Meridien Research /ID# 243508
    Orlando, Florida 32810, United States
  • Accel Research Sites - St Petersburg Clinical Research Unit /ID# 243091
    Saint Petersburg, Florida 33709-3113, United States
  • Meridian Clinical Research (Neurology) - Savannah /ID# 242689
    Savannah, Georgia 31406-2758, United States
  • Clinical Research Atlanta - Headlands LLC /ID# 242661
    Stockbridge, Georgia 30281-9054, United States
  • Allied Physicians - Fort Wayne Neurological Center /ID# 243511
    Fort Wayne, Indiana 46804, United States
  • Pharmasite Research, Inc. /ID# 243505
    Baltimore, Maryland 21208, United States
  • Medstar Georgetown Neurology /ID# 243289
    Chevy Chase, Maryland 20815, United States
  • QUEST Research Institute /ID# 243284
    Farmington Hills, Michigan 48334-2977, United States
  • Clinvest Research LLC /ID# 242597
    Springfield, Missouri 65807, United States
  • Princeton Center for Clinical Research /ID# 242652
    Skillman, New Jersey 08558, United States
  • Bio Behavioral Health, Inc /ID# 242643
    Toms River, New Jersey 08755-6434, United States
  • Dent Neurosciences Research Center, Inc. /ID# 242641
    Amherst, New York 14226, United States
  • Central New York Clinical Research /ID# 242593
    Manlius, New York 13104, United States
  • Rochester Clinical Research /ID# 242470
    New York, New York 14609, United States
  • PMG Research of Raleigh LLC /ID# 243286
    Raleigh, North Carolina 27609, United States
  • CTI Clinical Trial and Consulting /ID# 242884
    Cincinnati, Ohio 45212, United States
  • Aventiv Research Columbus /ID# 242462
    Columbus, Ohio 43213, United States
  • The Orthopedic Foundation /ID# 243292
    New Albany, Ohio 43054-8167, United States
  • Summit Research Network /ID# 242467
    Portland, Oregon 97210, United States
  • Abington Neurological Associates - Abington /ID# 243291
    Abington, Pennsylvania 19001, United States
  • WR-ClinSearch /ID# 242640
    Chattanooga, Tennessee 37421-1605, United States
  • FutureSearch Trials of Neurology /ID# 242690
    Austin, Texas 78731, United States
  • DiscoveResearch, Inc /ID# 242469
    Bryan, Texas 77802, United States
  • FutureSearch Trials of Dallas, LP /ID# 242658
    Dallas, Texas 75231, United States
  • Protenium Clinical Research /ID# 244067
    Hurst, Texas 76054, United States
  • ClinPoint Trials /ID# 242660
    Waxahachie, Texas 75165-1430, United States
  • Advanced Research Institute - Ridgeline /ID# 242662
    Ogden, Utah 84405-6779, United States
  • Highland Clinical Research /ID# 245159
    Salt Lake City, Utah 84124, United States
  • Core Clinical Research /ID# 244436
    Everett, Washington 98201, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Apr 2023, 12 months.

Results were first posted in Oct 2024, 1 year 6 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 12 months is below that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
Mar 7, 2022
Primary completionActual
Apr 4, 2023
CompletionActual
Apr 4, 2023
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05264129
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Mar 7, 2022
Primary completion
Apr 4, 2023
Completion
Apr 4, 2023
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atogepant · Ubrogepant

Start the discussion